Sign in to view content

A Model to Predict the 3-Year Risk of Needing Treatment for Diabetic Macular Edema

Bobeck S Modjtahedi, MD

Video
Published 2018

Related

Elevatum Study Design and Rationale: A Phase 4 Trial of Faricimab (VABYSMO) in Underrepresented Patients With Diabetic Macular Edema
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2023
Correlation Of Ganglion Cell Layer Damage And Diabetic Macular Ischemia Using OCT Angiography and Their Relationship With Visual Acuity in Diabetes
Dilraj S Grewal, MD, FASRS
On Demand Cases, Courses, and Papers
2017
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more